companydata.dkAptol Pharma ApS: Financial statements 2019
CVR: 39308967
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 0 and a net result of DKK -2,348 compared with DKK 128,964 the year before. Equity amounted to DKK 50,000. The solvency ratio was 100%.
- Revenue
- 0 kr.
- Gross Profit
- -101,800 kr.
- Profit/Loss
- -2,348 kr.
- Equity
- 50,000 kr.
- Total Assets
- 50,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
| 2018 | 0 | 89 t. | 129 t. | 50 t. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
As of December 13, 2019, Kira Gerber Astakhova has joined the board of directors of Aptol Pharma ApS.
On December 13, 2019, the company changed its name from Integrated biomedical technologies ApS to IBIO TECH ApS.
As of December 12, 2019, Kira Gerber Astakhova has left the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its interim report for the period February 5, 2018 – December 31, 2018.
About Aptol Pharma ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity amounted to DKK -140,336.